A Phase 1 Randomized Observer-Blind Study to Evaluate the Safety And Tolerability of a Vaccine Candidate Against Respiratory Syncytial Virus in Healthy Individuals 18 Through 49 Years of Age

Go Back to All Clinical Trials

A Phase 1 Randomized Observer-Blind Study to Evaluate the Safety And Tolerability of a Vaccine Candidate Against Respiratory Syncytial Virus in Healthy Individuals 18 Through 49 Years of Age

Brief description of study

The purpose of this study is to see if a new type of investigational Respiratory Syncytial Virus (RSV) vaccine called “modRNA RSV vaccine” is safe and can prompt the body to produce antibodies which may help protect people against RSV disease. The term “investigational vaccine” indicates that it has not yet been approved by health authorities.

Clinical Study Identifier: s24-00878

Principal Investigator: Lalitha Parameswaran.

Other Investigators: Robert Anwar Pitts, Mark J. Mulligan, Angelica Cifuentes Kottkamp, Madeline Alexandra DiLorenzo, Andrew Banks Fleming, Celia Engelson.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies